Eli Lilly and Company (LLY)vsNeuraxis, Inc. (NRXS)
LLY
Eli Lilly and Company
$1,372.99
+6.57%
HEALTHCARE · Cap: $1.12T
NRXS
Neuraxis, Inc.
$7.57
+2.85%
HEALTHCARE · Cap: $92.93M
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 1498480% more annual revenue ($79.67B vs $5.32M). LLY leads profitability with a 33.5% profit margin vs -144.4%. LLY earns a higher WallStSmart Score of 76/100 (B+).
LLY
Strong Buy76
out of 100
Grade: B+
NRXS
Avoid22
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for LLY.
Margin of Safety
-42.6%
Fair Value
$3.26
Current Price
$7.57
$4.31 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 79 in profit
Keeps 34 of every $100 in revenue as profit
Strong operational efficiency at 54.2%
Revenue surging 47.7% year-over-year
Earnings expanding 26.2% YoY
Revenue surging 115.7% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
Elevated debt levels
Premium valuation, high expectations priced in
Trading at 36.1x book value
Trading at 14.0x book value
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 33.5% and operating margin at 54.2%. Revenue growth of 47.7% demonstrates continued momentum.
Bull Case : NRXS
The strongest argument for NRXS centers on Revenue Growth, Debt/Equity. Revenue growth of 115.7% demonstrates continued momentum.
Bear Case : LLY
The primary concerns for LLY are Debt/Equity, P/E Ratio, Price/Book. A P/E of 42.2x leaves little room for execution misses. Debt-to-equity of 1.62 is elevated, increasing financial risk.
Bear Case : NRXS
The primary concerns for NRXS are Price/Book, EPS Growth, Market Cap.
Key Dynamics to Monitor
LLY profiles as a growth stock while NRXS is a hypergrowth play — different risk/reward profiles.
NRXS carries more volatility with a beta of 1.36 — expect wider price swings.
NRXS is growing revenue faster at 115.7% — sustainability is the question.
LLY generates stronger free cash flow (7.8B), providing more financial flexibility.
Bottom Line
LLY scores higher overall (76/100 vs 22/100), backed by strong 33.5% margins and 47.7% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Neuraxis, Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
NeurAxis, Inc. is a neuromodulation therapy device company in the United States. The company is headquartered in Versailles, Indiana.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?